Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

34.65CHF
15 Dec 2017
Change (% chg)

CHF3.65 (+11.77%)
Prev Close
CHF31.00
Open
CHF32.85
Day's High
CHF34.75
Day's Low
CHF31.60
Volume
193,912
Avg. Vol
67,105
52-wk High
CHF82.00
52-wk Low
CHF25.10

Chart for

About

Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone... (more)

Overall

Beta: 0.77
Market Cap(Mil.): CHF237.58
Shares Outstanding(Mil.): 6.29
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Santhera: negative opinion from the CHMP for Raxone in DMD

* SANTHERA RECEIVES NEGATIVE OPINION FROM THE CHMP FOR ITS MARKETING AUTHORIZATION APPLICATION FOR RAXONE® IN DMD AND INTENDS TO APPEAL THIS OPINION

15 Sep 2017

BRIEF-Santhera Pharmaceuticals Holding H1 net loss widens to CHF 22.7 million

* ‍1H 2017 SALES OF CHF 10.9 MILLION, INCREASE OF 51% COMPARED TO 1H 2016​

05 Sep 2017

BRIEF-Santhera announces approval of Raxone for LHON in Israel

* SANTHERA ANNOUNCES APPROVAL OF RAXONE FOR LHON IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Aug 2017

BRIEF-Santhera's Raxone receives first positive EAMS scientific opinion from UK's MHRA in Duchenne muscular dystrophy

* SANTHERA'S RAXONE RECEIVES FIRST POSITIVE EAMS SCIENTIFIC OPINION FROM UK'S MHRA IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

22 Jun 2017

Earnings vs. Estimates